China Resources Pharmaceutical (03320.HK) announced that its subsidiary China Resources Sanjiu's pediatric calming and brain-nourishing granules have obtained implied approval for clinical trials.

This product was jointly developed by China Resources Sanjiu, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen Institute for Drug Inspection and Research, and Shenzhen Traditional Chinese Medicine Manufacturing Innovation Center. It is classified as a new drug of Type 1.1 in traditional Chinese medicine, intended for children with tic disorders due to spleen deficiency and phlegm accumulation, as well as wind-phlegm disturbance. The company expects that obtaining this implied approval for clinical trials will help further enrich its product line and enhance the market competitiveness of its products